Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Agammaglobulinemia

ClinicalTrials.gov lists 38 trials for Agammaglobulinemia or a narrower condition beneath it. CSL Behring has the most among industry and government lead sponsors, with 5.

MeSH D000361 Hemic and Lymphatic Diseases C15 C20 Listed by Orphanet as a rare disease
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 2 Phase 1/2 Phase 1/2 2 Phase 2 Phase 2 5 Phase 2/3 Phase 2/3 4 Phase 3 Phase 3 14 Phase 4 Phase 4 1 Not applicable Not applicable 3 Observational Observational 7 Phase 1 Phase 1 2 Phase 1/2 Phase 1/2 2 Phase 2 Phase 2 5 Phase 2/3 Phase 2/3 4 Phase 3 Phase 3 14 Phase 4 Phase 4 1 Not applicable Not applicable 3 Observational Observational 7

Trials per phase

38 of the 38 trials are tagged with Agammaglobulinemia itself; the rest are tagged with a narrower condition beneath it.

Get the Agammaglobulinemia report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Agammaglobulinemia trials start? (19)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 4

1990: 1 trials (Observational 1) 2001: 2 trials (Phase 2/3 2) 2002: 3 trials (Not applicable 1, Phase 3 1, Phase 2 1) 2004: 2 trials (Phase 3 2) 2005: 2 trials (Phase 3 1, Phase 2 1) 2006: 1 trials (Phase 3 1) 2007: 1 trials (Phase 4 1) 2010: 2 trials (Phase 2 1, Phase 1/2 1) 2012: 2 trials (Observational 1, Phase 3 1) 2013: 1 trials (Observational 1) 2014: 3 trials (Not applicable 1, Phase 2/3 1, Phase 2 1) 2016: 1 trials (Phase 1 1) 2018: 3 trials (Observational 1, Not applicable 1, Phase 3 1) 2019: 1 trials (Phase 3 1) 2020: 3 trials (Observational 2, Phase 3 1) 2021: 1 trials (Phase 3 1) 2022: 4 trials (Observational 1, Phase 3 1, Phase 2/3 1, Phase 1 1) 2025: 2 trials (Phase 3 1, Phase 2 1)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 3
2025 2
2022 4
2021 1
2020 3
2019 1
2018 3
2016 1
2014 3
2013 1

Showing 10 of 19 earlier years.

Start your 14-day trial Email me all 19 earlier years as a PDF

No forecast is made for this condition: it averages 1.6 trial starts a year over the five years to September, under the 5 a year the method needs.

Prediction, not a registry value: median of 36 months from start to primary completion across 8 trials still running at the 2026-10-09 snapshot; registered median of 28 months across 18 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Agammaglobulinemia trials in? (8)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 2
Phase 1/2 2
Phase 2 5
Phase 2/3 4
Phase 3 14
Phase 4 1
Not applicable 3
Observational 7

How many Agammaglobulinemia trials are recruiting? (7)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Recruiting 9
Enrolling by invitation 1
Active, not recruiting 1
Completed 20
Terminated 2

Showing 5 of 7 statuses.

Start your 14-day trial Email me all 7 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Agammaglobulinemia trials? (8)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
CSL Behring 5
National Institute of Allergy and Infectious Diseases (NIAID) 4
Kedrion S.p.A. 3
Grifols Therapeutics LLC 2
Octapharma 2

Showing 5 of 8 sponsors.

Start your 14-day trial Email me all 8 sponsors as a PDF

Which drugs are being tested for Agammaglobulinemia? (2)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Immunoglobulin 2
Plerixafor 2

Interventions as named in the registry (13)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Globulin, Immune 4
Kedrion IVIG 10% 3
Immunoglobulins Intravenous (Human) 3
IgPro20 2
IVIG 2

Showing 5 of 13 interventions.

Start your 14-day trial Email me all 13 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Agammaglobulinemia trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Fever 3 1
Infection 3 1
Thrombosis 3 2
Arthritis 2 1
Cellulitis 2 2

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Agammaglobulinemia? (104)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Long-Term Safety and Efficacy of Gene Therapy for Adenosine Deaminase Deficiency. The New England journal of medicine 2025 Yes
Long-term and real-world safety and efficacy of retroviral gene therapy for adenosine deaminase deficiency. Nature medicine 2024 Yes
Use of Rituximab in Childhood Idiopathic Nephrotic Syndrome. Clinical journal of the American Society of Nephrology : CJASN 2023 Yes
Effect of rituximab on immune status in children with mature B-cell non-Hodgkin lymphoma: a prespecified secondary analysis of the Inter-B-NHL Ritux 2010 trial. The Lancet. Haematology 2023 Yes
Monitoring, prophylaxis, and treatment of infections in patients with MM receiving bispecific antibody therapy: consensus recommendations from an expert panel. Blood cancer journal 2023 Yes

Showing 5 of 104 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Prevalence (27)

Shown in this order: jurisdiction, then disease name. Orphanet observation for the mapped ORPHA concept; the mapping relation column says whether that concept is exactly this condition or broader or narrower.

Prevalence
Orphanet disease Type Class Geography Jurisdiction Mapping relation
Agammaglobulinemia Point prevalence <1 / 1 000 000 United Kingdom GB Unspecified
Agammaglobulinemia Point prevalence <1 / 1 000 000 United Kingdom GB Exact
Agammaglobulinemia Point prevalence <1 / 1 000 000 United Kingdom GB Exact
Agammaglobulinemia Point prevalence <1 / 1 000 000 Turkey Not stated Unspecified
Agammaglobulinemia Point prevalence 1-9 / 1 000 000 France Not stated Unspecified

Showing 5 of 27 prevalence observations.

Start your 14-day trial Email me all 27 prevalence observations as a PDF

Rare-disease identity (2)

Shown in this order: exact, broader, narrower, other.

Rare-disease identity
Orphanet disease ORPHA code Relation Source
Agammaglobulinemia 183669 Exact Orphadata Science knowledge files, Product 1
Agammaglobulinemia 183669 Exact Orphanet Rare Disease Ontology (ORDO)

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: sub-conditions in mesh.

Browse all condition evidence pages